


Rutgers University-New Brunswick, 2019 Outbreak Response:



Evaluation of high-risk persons for MenB vaccination



Does the person have documentation of receiving MenB vaccine?

No or Unknown

Did the person complete a primary series with:

Bexsero® – 2 Dose

OR

Trumenba® - 3 Dose

OR

Trumenba® – 2 Dose

Administer:

Bexsero® – 2 Dose

OR

Trumenba® – 3 Dose



No



Was most recent dose received ≥1 year from today's date?



No

Administer booster dose (using the same MenB vaccine product used to complete primary series) No further doses needed at this time. Schedule booster dose for ≥1 year from date of most recent dose.

Complete primary series as follows:

(using the same MenB vaccine product previously administered)

Bexsero®

If ≥1 month since Dose 1 (no maximum interval) - administer
Dose 2

OR

Trumenba®

If only Dose 1 received:

- If ≥ 6 months after Dose 1 (no maximum interval) administer Dose 2 as final dose of primary series
- If ≥1 month and < 6 months after Dose 1 administer Dose
 2 and schedule Dose 3 with minimum interval of 4 months
 between Dose 2 & 3

If Dose 1 & Dose 2 received:

- If Dose 1 & 2 are ≥ 1 month AND < 6 months apart –
 administer Dose 3 as final dose primary series, ensuring that Dose 3 is administered ≥4 months from Dose 2
- NOTE: If Dose 1 & 2 are administered ≥6 months apart, primary series is considered complete (evaluate individual for booster dose)

MenB Primary Series Schedule

Bexsero® (MenB-4C) Trumenba® (MenB-FHbp) – 3 Dose Trumenba® (MenB-FHbp) – 2 Dose

Dose 1: 0 months Dose 1: 0 months Dose 1: 0 months

Dose 2: 1 month Dose 2: 1-2 months Dose 2: 2 - 2 months

Dose 3: 6 months (≥4 months between Dose 2 & 3)